세계의 브루셀라병 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)
Global Brucellosis Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
상품코드:1542614
리서치사:Value Market Research
발행일:2024년 07월
페이지 정보:영문 223 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
브루셀라병 백신 시장의 세계 수요는 2023년의 2억 7,938만 달러에서 2032년에는 4억 4,128만 달러 규모에 이르고, 조사 기간 2024-2032년의 CAGR은 5.21%를 나타낼 것으로 추정됩니다.
브루셀라병은 몰타열, 파상열, 지중해열로도 알려져 있으며 감염된 동물의 가열 불충분한 고기, 미살균 우유 섭취 또는 분비물과의 밀접한 접촉으로 인한 감염입니다. 브루셀라병 백신은 소, 양, 염소용입니다. 현재 인간에 대한 백신이 없습니다. 예방 접종은 동물의 질병에 대한 저항력을 높이는 면역 반응을 생성하여 기능하며 브루셀라병을 제어, 관리 및 제거하는 데 중요합니다.
시장 역학
가축 생산 증가와 동물을 매개로 하는 감염증의 위협이 시장의 성장을 견인하고 있습니다. 축산 부문의 지속적인 성장과 변화에 따라 식량 안보와 인간 영양과 관련된 주요 과제가 제공됩니다. 축산물 수요는 우유, 고기, 계란의 소비량 증가에 의해 영향을 받고 있습니다. 세계적으로 브루셀라증은 가장 흔한 인류 공통 감염으로 여겨지며, 연간 50만 건 이상의 사례가 기록되어 있습니다. 시장 성장은 예방 접종 프로그램에 의해 지원됩니다. 한편, 효과적인 진단이나 치료를 할 수 없는 지역이나 인간이나 동물에 대한 감염의 검출이나 예방을 위한 프로그램이 충분히 실시되지 않은 지역도 많이 존재합니다. 이러한 지역에서는 브루셀라증의 예방과 통제를 돕기 위해 정부의 수의부와 보건 부문의 협력과 협력이 필요합니다.
이 설문 조사 보고서는 Porter's Five Force 모델, 시장 매력 분석 및 밸류체인 분석을 다룹니다. 이러한 도구는 업계의 구조를 명확하게 파악하고 세계 수준에서 경쟁의 매력을 평가하는 데 도움이 됩니다. 또한, 이러한 도구는 브루셀라병 백신 세계 시장에서 각 부문을 종합적으로 평가할 수 있습니다. 브루셀라병 백신 산업의 성장과 동향은 이 연구에 대한 전반적인 접근법을 설명합니다.
시장 세분화
시장 세분화는 국가별 및 지역별 부문에 대한 자세한 데이터를 제공하여 각 제품 서비스의 대상 계층과 미래의 비즈니스 기회를 파악합니다.
지역 분석
이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카에서 브루셀라 병 백신 시장의 현재 및 미래 수요를 강조하는 지역 전망을 다룹니다. 또한 이 보고서는 모든 주요 지역에서 개별 용도 부문에 대한 수요, 추정 및 예측에 중점을 둡니다.
요청이 있으시면 저희에게 연락하십시오. 당사의 설문조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.
The global demand for Brucellosis Vaccines Market is presumed to reach the market size of nearly USD 441.28 Million by 2032 from USD 279.38 Million in 2023 with a CAGR of 5.21% under the study period 2024-2032.
Brucellosis also is known as malta fever, undulant fever, Mediterranean fever, is an infection caused by undercooked meat of infected animals or ingestion of unpasteurized milk or close contact with their secretion. Brucellosis vaccine is meant for cattle, sheep and goats. Currently, there is no vaccine available for humans. Vaccination works by producing an immune response that increases the animal's resistance to the diseases and is important to control, manage and eliminate brucellosis.
MARKET DYNAMICS
Growing livestock production and the threat of animal-borne infectious diseases are driving the growth of the market. With continuous growth and transformation of the livestock sector offer substantial challenges associated with food security and human nutrition. Demand for livestock products is growing influenced by increasing consumption of milk, meat, and eggs. Globally, brucellosis is considered as the most common zoonotic disease, with more than 500,000 cases recorded annually. Growth of the market is backed by a vaccination programme. On the other hand, there are many regions where effective diagnosis or treatment is not available or where programmes for the detection and prevention of the infection in humans and animals are not adequately carried out. Such regions need co-ordination and collaboration between veterinary and health sectors of government to help prevent and control brucellosis.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Brucellosis Vaccines. The growth and trends of Brucellosis Vaccines industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Brucellosis Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Brucellosis Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Brucellosis Vaccines market include Merck & Co. Inc., Laboratories Tornel, Hester Biosciences Limited, Ceva, CZ Vaccines. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Route of Administration
3.7.3 Market Attractiveness Analysis By Disease Indication
3.7.4 Market Attractiveness Analysis By Age
3.7.5 Market Attractiveness Analysis By Distribution Channel
3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY TYPE
5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines) Historic and Forecast Sales By Regions
5.4. Inactivated Historic and Forecast Sales By Regions
5.5. Live Attenuated Historic and Forecast Sales By Regions
5.6. mRNA Aaccines Historic and Forecast Sales By Regions
5.7. Viral Vector Vaccines Historic and Forecast Sales By Regions
6. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Parenteral Historic and Forecast Sales By Regions
6.5. Nasal Historic and Forecast Sales By Regions
7. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISEASE INDICATION
7.1. Overview By Disease Indication
7.2. Historical and Forecast Data Analysis By Disease Indication
7.3. Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Historic and Forecast Sales By Regions
7.4. Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Historic and Forecast Sales By Regions
7.5. Cancer Vaccines Historic and Forecast Sales By Regions
7.6. Allergy Vaccines Historic and Forecast Sales By Regions
8. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY AGE
8.1. Overview By Age
8.2. Historical and Forecast Data Analysis By Age
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adult Historic and Forecast Sales By Regions
9. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data Analysis By Distribution Channel
9.3. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
9.4. Government Suppliers Historic and Forecast Sales By Regions
9.5. Others Historic and Forecast Sales By Regions
10. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY GEOGRAPHY
10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
10.3.1 Overview, Historic and Forecast Data Sales Analysis
10.3.2 North America By Segment Sales Analysis
10.3.3 North America By Country Sales Analysis
10.3.4 United States Sales Analysis
10.3.5 Canada Sales Analysis
10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
10.4.1 Overview, Historic and Forecast Data Sales Analysis
10.4.2 Europe By Segment Sales Analysis
10.4.3 Europe By Country Sales Analysis
10.4.4 United Kingdom Sales Analysis
10.4.5 France Sales Analysis
10.4.6 Germany Sales Analysis
10.4.7 Italy Sales Analysis
10.4.8 Russia Sales Analysis
10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
10.5.1 Overview, Historic and Forecast Data Sales Analysis
10.5.2 Asia Pacific By Segment Sales Analysis
10.5.3 Asia Pacific By Country Sales Analysis
10.5.4 China Sales Analysis
10.5.5 India Sales Analysis
10.5.6 Japan Sales Analysis
10.5.7 South Korea Sales Analysis
10.5.8 Australia Sales Analysis
10.5.9 South East Asia Sales Analysis
10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
10.6.1 Overview, Historic and Forecast Data Sales Analysis
10.6.2 Latin America By Segment Sales Analysis
10.6.3 Latin America By Country Sales Analysis
10.6.4 Brazil Sales Analysis
10.6.5 Argentina Sales Analysis
10.6.6 Peru Sales Analysis
10.6.7 Chile Sales Analysis
10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
10.7.1 Overview, Historic and Forecast Data Sales Analysis
10.7.2 Middle East & Africa By Segment Sales Analysis
10.7.3 Middle East & Africa By Country Sales Analysis
10.7.4 Saudi Arabia Sales Analysis
10.7.5 UAE Sales Analysis
10.7.6 Israel Sales Analysis
10.7.7 South Africa Sales Analysis
10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE BRUCELLOSIS VACCINES COMPANIES
11.1. Brucellosis Vaccines Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments
12. COMPANY PROFILES OF BRUCELLOSIS VACCINES INDUSTRY
12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Merck & Co. Inc.
12.3.1 Company Overview
12.3.2 Company Revenue
12.3.3 Products
12.3.4 Recent Developments
12.4. Laboratories Tornel
12.4.1 Company Overview
12.4.2 Company Revenue
12.4.3 Products
12.4.4 Recent Developments
12.5. Hester Biosciences Limited
12.5.1 Company Overview
12.5.2 Company Revenue
12.5.3 Products
12.5.4 Recent Developments
12.6. Ceva
12.6.1 Company Overview
12.6.2 Company Revenue
12.6.3 Products
12.6.4 Recent Developments
12.7. CZ Vaccines
12.7.1 Company Overview
12.7.2 Company Revenue
12.7.3 Products
12.7.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
